{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,10]],"date-time":"2026-04-10T10:27:51Z","timestamp":1775816871140,"version":"3.50.1"},"reference-count":18,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2016,12,22]],"date-time":"2016-12-22T00:00:00Z","timestamp":1482364800000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Am J Clin Dermatol"],"published-print":{"date-parts":[[2017,2]]},"DOI":"10.1007\/s40257-016-0242-0","type":"journal-article","created":{"date-parts":[[2016,12,22]],"date-time":"2016-12-22T19:21:35Z","timestamp":1482434495000},"page":"139-145","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":29,"title":["Dapsone 7.5% Gel: A Review in Acne Vulgaris"],"prefix":"10.1007","volume":"18","author":[{"given":"Zaina T.","family":"Al-Salama","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Emma D.","family":"Deeks","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2016,12,22]]},"reference":[{"issue":"5","key":"242_CR1","doi-asserted-by":"crossref","first-page":"945","DOI":"10.1016\/j.jaad.2015.12.037","volume":"74","author":"AL Zaenglein","year":"2016","unstructured":"Zaenglein AL, Pathy AL, Schlosser BJ, et al. Guidelines of care for the management of acne vulgaris. J Am Acad Dermatol. 2016;74(5):945\u2013973.e33.","journal-title":"J Am Acad Dermatol."},{"issue":"9813","key":"242_CR2","doi-asserted-by":"crossref","first-page":"361","DOI":"10.1016\/S0140-6736(11)60321-8","volume":"379","author":"HC Williams","year":"2012","unstructured":"Williams HC, Dellavalle RP, Garner S. Acne vulgaris. Lancet. 2012;379(9813):361\u201372.","journal-title":"Lancet"},{"issue":"1 Suppl 1","key":"242_CR3","first-page":"S11","volume":"15","author":"JA Zeichner","year":"2016","unstructured":"Zeichner JA. Inflammatory acne treatment: review of current and new topical therapeutic options. J Drugs Dermatol. 2016;15(1 Suppl 1):S11\u20136.","journal-title":"J Drugs Dermatol."},{"issue":"9","key":"242_CR4","first-page":"27","volume":"6","author":"EA Tanghetti","year":"2013","unstructured":"Tanghetti EA. The role of inflammation in the pathology of acne. J Clin Aesthet Dermatol. 2013;6(9):27\u201335.","journal-title":"J Clin Aesthet Dermatol"},{"issue":"4","key":"242_CR5","doi-asserted-by":"crossref","first-page":"221","DOI":"10.2165\/00128071-200910040-00002","volume":"10","author":"M Stotland","year":"2009","unstructured":"Stotland M, Shalita AR, Kissling RF. Dapsone 5% gel: a review of its efficacy and safety in the treatment of acne vulgaris. Am J Clin Dermatol. 2009;10(4):221\u20137.","journal-title":"Am J Clin Dermatol"},{"key":"242_CR6","unstructured":"Allergan Inc. Aczone\u00ae (dapsone) gel, 7.5%, for topical use: US prescribing information. 2016. https:\/\/www.aczone.com . Accessed 29 Nov 2016."},{"key":"242_CR7","unstructured":"Food and Drug Administration. Clinical pharmacology and biopharmaceutics review(s): dapsone 5% gel. 2005. http:\/\/www.accessdata.fda.gov\/ . Accessed 29 Nov 2016."},{"issue":"10","key":"242_CR8","first-page":"1250","volume":"15","author":"MT Jarratt","year":"2016","unstructured":"Jarratt MT, Jones TM, Chang-Lin J-E, et al. Safety and pharmacokinetics of once-daily dapsone gel, 7.5% in patients with moderate acne vulgaris. J Drugs Dermatol. 2016;15(10):1250\u20139.","journal-title":"J Drugs Dermatol"},{"issue":"10","key":"242_CR9","first-page":"981","volume":"6","author":"AW Lucky","year":"2007","unstructured":"Lucky AW, Maloney JM, Roberts J, et al. Dapsone gel 5% for the treatment of acne vulgaris: safety and efficacy of long-term (1 year) treatment. J Drugs Dermatol. 2007;6(10):981\u20137.","journal-title":"J Drugs Dermatol"},{"issue":"5","key":"242_CR10","first-page":"553","volume":"15","author":"LF Stein Gold","year":"2016","unstructured":"Stein Gold LF, Jarratt MT, Bucko AD, et al. Efficacy and safety of once-daily dapsone gel, 7.5% for treatment of adolescents and adults with acne vulgaris: first of two identically designed, large, multicenter, randomized, vehicle-controlled trials. J Drugs Dermatol. 2016;15(5):553\u201361.","journal-title":"J Drugs Dermatol"},{"issue":"8","key":"242_CR11","first-page":"962","volume":"15","author":"LF Eichenfield","year":"2016","unstructured":"Eichenfield LF, Lain T, Frankel EH, et al. Efficacy and safety of once-daily dapsone gel 7.5% for treatment of adolescents and adults with acne vulgaris: second of two identically designed, large, multicenter, randomized, vehicle-controlled trials. J Drugs Dermatol. 2016;15(8):962\u20139.","journal-title":"J Drugs Dermatol"},{"issue":"10","key":"242_CR12","first-page":"19","volume":"9","author":"DM Thiboutot","year":"2016","unstructured":"Thiboutot DM, Kircik L, McMichael A, et al. Efficacy, safety, and dermal tolerability of dapsone gel, 7.5% in patients with moderate acne vulgaris: a pooled analysis of two phase 3 trials. J Clin Aesthet Dermatol. 2016;9(10):19\u201327.","journal-title":"J Clin Aesthet Dermatol"},{"issue":"5 Suppl 1","key":"242_CR13","first-page":"AB2","volume":"74","author":"ZD Draelos","year":"2016","unstructured":"Draelos ZD, Rodriguez DA, Kempers SE, et al. Age and gender as predictors of treatment outcomes with once-daily dapsone 7.5% topical gel for acne vulgaris [abstract no. 3244 plus poster]. J Am Acad Dermatol. 2016;74(5 Suppl 1):AB2.","journal-title":"J Am Acad Dermatol"},{"issue":"2","key":"242_CR14","doi-asserted-by":"crossref","first-page":"e20153186","DOI":"10.1542\/peds.2015-3186","volume":"138","author":"DM Graff","year":"2016","unstructured":"Graff DM, Bosse GM, Sullivan J. Case report of methemoglobinemia in a toddler secondary to topical dapsone exposure. Pediatrics. 2016;138(2):e20153186.","journal-title":"Pediatrics"},{"issue":"5","key":"242_CR15","doi-asserted-by":"crossref","first-page":"491","DOI":"10.1056\/NEJMc1408272","volume":"372","author":"GS Swartzentruber","year":"2015","unstructured":"Swartzentruber GS, Yanta JH, Pizon AF. Methemoglobinemia as a complication of topical dapsone. N Engl J Med. 2015;372(5):491\u20132.","journal-title":"N Engl J Med"},{"issue":"3","key":"242_CR16","doi-asserted-by":"crossref","first-page":"439. e1","DOI":"10.1016\/j.jaad.2006.10.005","volume":"56","author":"ZD Draelos","year":"2007","unstructured":"Draelos ZD, Carter E, Maloney JM, et al. Two randomized studies demonstrate the efficacy and safety of dapsone gel, 5% for the treatment of acne vulgaris. J Am Acad Dermatol. 2007;56(3):439. e1\u201310.","journal-title":"J Am Acad Dermatol"},{"issue":"5 Suppl","key":"242_CR17","doi-asserted-by":"crossref","first-page":"S1","DOI":"10.1016\/j.jaad.2009.01.019","volume":"60","author":"D Thiboutot","year":"2009","unstructured":"Thiboutot D, Gollnick H, Bettoli V, et al. New insights into the management of acne: an update from the Global Alliance to Improve Outcomes in Acne Group. J Am Acad Dermatol. 2009;60(5 Suppl):S1\u201350.","journal-title":"J Am Acad Dermatol"},{"issue":"3","key":"242_CR18","doi-asserted-by":"crossref","first-page":"524","DOI":"10.1111\/j.1365-2133.2005.07047.x","volume":"154","author":"N Kellett","year":"2006","unstructured":"Kellett N, West F, Finlay AY. Conjoint analysis: a novel, rigorous tool for determining patient preferences for topical antibiotic treatment for acne. A randomised controlled trial. Br J Dermatol. 2006;154(3):524\u201332.","journal-title":"Br J Dermatol"}],"container-title":["American Journal of Clinical Dermatology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s40257-016-0242-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s40257-016-0242-0\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s40257-016-0242-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2017,6,25]],"date-time":"2017-06-25T06:33:08Z","timestamp":1498372388000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s40257-016-0242-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,12,22]]},"references-count":18,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2017,2]]}},"alternative-id":["242"],"URL":"https:\/\/doi.org\/10.1007\/s40257-016-0242-0","relation":{},"ISSN":["1175-0561","1179-1888"],"issn-type":[{"value":"1175-0561","type":"print"},{"value":"1179-1888","type":"electronic"}],"subject":[],"published":{"date-parts":[[2016,12,22]]}}}